Incidence, outcomes, and impact of COVID‐19 on inflammatory bowel disease: propensity matched research network analysis

• DOI: 10.1111/apt.16730
• Publication Date: 2021-12-14T08:17:22Z
• Authors: Yousaf Hadi; Parambir S. Dulai; Justin Kupec; Nabeeha Mohy‐Ud‐Din; Vipul Jairath; Francis A. Farraye; Gursimran S. Kochhar
• Keywords: Cohort Studies; 03 medical and health sciences; 0302 clinical medicine; SARS-CoV-2; Incidence; COVID-19; Humans; Inflammatory Bowel Diseases; Retrospective Studies; 3. Good health

SummaryBackgroundAccurate estimates for the risk of COVID‐19 in IBD, and an understanding of the impact of COVID‐19 on IBD course and the risk of incident post‐infectious IBD are needed.AimsTo estimate the risk of COVID‐19 in IBD and study its impact on IBD course and the risk of incident post‐infectious IBD.MethodsA retrospective propensity score matched cohort study utilising multi‐institutional research network TriNetX. COVID‐19 patients with and without IBD were identified to quantify the risk of COVID‐19 in patients with IBD, COVID‐19 outcomes in patients with IBD and the impact of COVID‐19 on IBD disease course. The risk of incident post‐infectious IBD in COVID‐19 patients was compared to the population not infected with COVID‐19 during a similar time period.ResultsIncidence rate ratio for COVID‐19 was lower in IBD patients compared to the non‐IBD population (0.79, 95% CI: 0.72‐0.86). COVID‐19‐infected patients with IBD were at increased risk for requiring hospitalisation compared to non‐IBD population (RR: 1.17, 95% CI: 1.02‐1.34) with no differences in need for mechanical ventilation or mortality. Patients with IBD on steroids were at an increased risk for critical care need (RR: 2.22, 95% CI: 1.29‐3.82). Up to 7% of patients with IBD infected with COVID‐19 suffered an IBD flare 3‐months post‐infection. Risk for incident IBD post‐COVID was lower than that seen in the non‐COVID population (RR: 0.64, 95% CI: 0.54‐0.65).ConclusionWe observed no increase in risk for COVID‐19 amongst patients with IBD or risk for de novo IBD after COVID‐19 infection. We confirmed prior observations regarding the impact of steroid use on COVID‐19 severity in patients with IBD.